Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Post Q1 2025 Earnings of ($1.06) Per Share, Zacks Research Forecasts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Zacks Research cut their Q1 2025 EPS estimates for Alnylam Pharmaceuticals in a report issued on Wednesday, June 26th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of ($1.06) for the quarter, down from their prior estimate of ($0.95). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($3.92) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.58) EPS, Q1 2026 earnings at $0.31 EPS and FY2026 earnings at $2.58 EPS.

Other research analysts also recently issued research reports about the stock. SVB Leerink raised their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research report on Tuesday, June 25th. Citigroup lifted their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Bank of America upped their target price on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Morgan Stanley lifted their price target on Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an “equal weight” rating in a report on Tuesday, June 25th. Finally, Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research note on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $246.41.

Alnylam Pharmaceuticals Trading Up 1.8 %

Shares of Alnylam Pharmaceuticals stock opened at $247.61 on Monday. The stock’s fifty day moving average price is $163.85 and its 200-day moving average price is $165.40. The firm has a market cap of $31.32 billion, a P/E ratio of -92.39 and a beta of 0.37. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. The company’s revenue for the quarter was up 54.8% compared to the same quarter last year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. GAMMA Investing LLC raised its holdings in Alnylam Pharmaceuticals by 97.2% in the 2nd quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 205 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in shares of Alnylam Pharmaceuticals by 8.1% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock valued at $4,964,000 after buying an additional 2,500 shares in the last quarter. Cetera Advisors LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $238,000. Burney Co. lifted its position in shares of Alnylam Pharmaceuticals by 371.9% during the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock valued at $4,044,000 after buying an additional 21,325 shares in the last quarter. Finally, Swedbank AB acquired a new stake in Alnylam Pharmaceuticals in the 1st quarter valued at $3,084,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares in the company, valued at $18,602,548.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares in the company, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The disclosure for this sale can be found here. Insiders sold a total of 67,357 shares of company stock worth $13,436,711 over the last three months. 1.50% of the stock is currently owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.